Evidence map›Paper›PMID 33832450›Full record

ArticleBMC infectious diseases2021

Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.

Benjamin Amoani, Ben Gyan, Samuel Asamoah Sakyi, Emmanuel Kwasi Abu, Samuel Victor Nuvor, Precious Barnes, Tracy Sarkodie-Addo, Benjamin Ahenkorah, Christian Sewor, Duah Dwomoh and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Pre-vaccinationFrontiers in immunology · 2024
    Trial
  2. Article
  3. Review
  4. Cloning and Recombinant Protein Expression in Lactococcus lactis.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  5. Article
  6. Health science reports · 2022
    Article
  7. Article
  8. Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Benjamin AmoaniDepartment of Biomedical Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
Ben GyanDepartment of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
Samuel Asamoah SakyiDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. samasamoahsakyi@yahoo.co.uk.
Emmanuel Kwasi AbuDepartment of Optometry, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
Samuel Victor NuvorDepartment of Microbiology and Immunology, School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana.
Precious BarnesDepartment of Physician Assistant, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
Tracy Sarkodie-AddoDepartment of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
Benjamin AhenkorahDepartment of Molecular Medicine, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Christian SeworDepartment of Biomedical Science, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana.
Duah DwomohDepartment of Biostatistics, School of Public Health, University of Ghana, Accra, Ghana.
Michael TheisenDepartment for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark.
Michael CappelloPartnerships for Global Health, Department of Pediatrics, Yale School of Medicine, Yale University, New Haven, CT, USA.
Michael D WilsonParasitology Department, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
Bright AduDepartment of Immunology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana.
University of Cape Coast · GHUniversity of Ghana · GHKwame Nkrumah University of Science and Technology · GHNoguchi Memorial Institute for Medical Research · GHUniversity of Copenhagen · DKYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalaria and helminths diseases are co-endemic in most parts of sub-Saharan Africa. Immune responses from each of these pathogens interact, and these interactions may have implications on vaccines. The GMZ2 malaria vaccine candidate is a fusion protein of Plasmodium falciparum merozoite surface protein 3 (MSP3) and glutamate rich protein (GLURP R0). GMZ2 has recently showed modest efficacy in a phase IIb multicenter trial. Here, we assessed the effect of hookworm (Necator americanus) infection and anthelmintic treatment on naturally acquired antibody responses against GMZ2 and constituent antigens.

methodsThis longitudinal cross-sectional study was conducted in the Kintampo North Municipality of Ghana. Blood and stool samples were taken from 158 individuals (4-88 years old) infected with either P. falciparum alone (n = 59) or both hookworm and P. falciparum (n = 63) and uninfected endemic controls (n = 36). Stool hookworm infection was detected by the Kato-Katz method and PCR. Malaria parasitaemia was detected by RDT, light microscopy and P. falciparum-specific 18S rRNA gene PCR. Serum samples were obtained prior to hookworm treatment with a single dose of albendazole (400 mg) and 3 weeks (21 days) after treatment. Levels of IgG1, IgG3 and IgM against GMZ2, MSP3 and GLURP R0 were measured by ELISA and compared among the groups, before and after treatment.

resultsParticipants with P. falciparum and hookworm co-infection had significantly higher IgG3 levels to GMZ2 than those with only P. falciparum infection and negative control (p < 0.05) at baseline. Treatment with albendazole led to a significant reduction in IgG3 levels against both GMZ2 and GLURP R0. Similarly, IgM and IgG1 levels against MSP3 also decreased following deworming treatment.

conclusionIndividuals with co-infection had higher antibody responses to GMZ2 antigen. Treatment of hookworm/malaria co-infection resulted in a reduction in antibody responses against GMZ2 and constituent antigens after albendazole treatment. Thus, hookworm infection and treatment could have a potential implication on malaria vaccine efficacy.

Indexed as

AdolescentAdultAgedAged, 80 and overAlbendazoleAnthelminticsAntibodies, ProtozoanAntigens, ProtozoanCase-Control StudiesChildChild, PreschoolCross-Sectional StudiesFemaleHookworm InfectionsHumansImmunoglobulin GAlbendazoleAnthelminticsAntibodies, ProtozoanAntigens, Protozoanglutamate-rich protein, PlasmodiumGMZ2 vaccineImmunoglobulin GMalaria Vaccinesmerozoite surface protein 3, PlasmodiumProtozoan Proteins

Identifiers

PMID33832450
PMCPMC8028774
OpenAlexW3152211273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.